There is no FDA-authorized genetic test for Alzheimer's risk in the United States, so any document, letter, or marketing page claiming an "FDA-approved dementia gene test" is wrong on its face. Verifying genetics in a dementia care claim in 2026 means checking three separate things: whether the lab is CLIA-certified, whether the result is being used for what it can actually support, and whether the benefit you are chasing depends on genetics at all — for Medicare's anti-amyloid coverage, it does not.
APOE is the gene most often at issue. Its ε4 variant raises the risk of late-onset Alzheimer's disease and lowers the typical age of onset, but it is a risk marker, not a diagnosis. The rest of this guide covers what the FDA label actually says, what CMS actually requires, which sources to check, and the red flags that mean a claim is being oversold.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Explore the official data from FDA — Use this primary source to review the underlying data.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- What the FDA record really says about APOE testing
- Medicare coverage does not turn on your genotype
- Who regulates the test you were actually given
- Red flags in a genetics-based dementia care claim
- The insurance exposure nobody mentions at the point of sale
- The diagnostic route that is actually FDA-cleared
- Frequently Asked Questions
What the FDA record really says about APOE testing
The prescribing information for Leqembi (lecanemab-irmb) is the clearest statement available. The FDA label for Leqembi says plainly that an FDA-authorized test for detecting ApoE ε4 alleles is not currently available, and that the tests in use "may vary in accuracy and design." That single sentence disposes of most inflated claims. The label still recommends ApoE ε4 genotyping before treatment starts — not to decide eligibility, but to gauge the risk of amyloid-related imaging abnormalities, or ARIA, which is brain swelling or small bleeds visible on MRI.
In the trial data the FDA cites, ARIA occurred in 45% of ε4 homozygotes (two copies) taking Leqembi against 22% on placebo, 19% of heterozygotes (one copy) against 9%, and 13% of noncarriers against 4%. Two things follow. Genotyping here is a safety conversation, not a gate: the same label states patients may be treated even if they have not been tested. And a test used for that purpose is a laboratory test ordered by a clinician, not a consumer kit.
Medicare coverage does not turn on your genotype
If the claim in question is Medicare coverage of an anti-amyloid antibody, genetics is not the trigger. Under CMS national coverage determination 200.3, effective April 7, 2022, these drugs are covered only through Coverage with Evidence Development. The patient must have mild cognitive impairment or mild Alzheimer's dementia, must have confirmed amyloid beta pathology, and the prescribing clinician must submit data to a CMS-approved registry. Confirmed amyloid pathology is a different measurement from APOE status.
Amyloid is the protein deposit itself, shown by imaging, spinal fluid, or now a cleared blood test; APOE is inherited and never changes. someone with two ε4 copies and no amyloid does not meet the coverage criteria, and someone with no ε4 allele and confirmed amyloid does. Check the NCD text yourself before accepting anyone's summary of it, and ask the prescribing practice which CMS-approved registry they submit to. A practice that cannot name one is not meeting the coverage condition.
Who regulates the test you were actually given
Most clinical genetic tests for dementia are laboratory-developed tests — assays designed, validated, and run inside a single lab, with no FDA premarket review. The FDA tried to change that with a May 2024 rule, and on March 31, 2025 the US District Court for the Eastern District of Texas vacated it in *ACLA v. FDA*; per the Congressional Research Service analysis and reporting from the American Hospital Association, HHS did not appeal. So verification falls back on CLIA certification and the lab's own validation data.
Ask for both in writing. Direct-to-consumer results sit in a different category again. FDA's April 2017 de novo authorization for the 23andMe Genetic Health Risk reports is explicit, in the FDA's own announcement, that these tests are not for diagnosis, for treatment decisions, or for describing current health status. A consumer report is not evidence for a care or benefits claim, and submitting one as though it were will not survive review.
Red flags in a genetics-based dementia care claim
.
- "FDA-approved genetic test for Alzheimer's." No such authorization exists for clinical use; the Leqembi label says so directly.
- A consumer DTC report offered as diagnostic proof, or as the basis for a treatment or benefits decision.
- A claim that ε4 status alone qualifies someone for Medicare-covered anti-amyloid treatment. The NCD requires amyloid pathology and registry participation.
- A genotype result presented as a diagnosis. NIA's Alzheimer's disease genetics fact sheet notes that some ε4 carriers never develop Alzheimer's; FDA's de novo review records that up to 75% of heterozygous carriers never develop the disease, and up to half of patients with the disease carry no ε4 allele at all.
- No named CLIA-certified performing lab, no accession number, no validation data on request.
The insurance exposure nobody mentions at the point of sale
Getting an APOE result to support a care claim can cost you later, in a way the test's marketing will not raise. The Genetic Information Nondiscrimination Act of 2008 bars genetic discrimination in health insurance and employment — and, as the National Human Genome Research Institute explains, it does not cover long-term care, life, or disability insurance. That is the exact gap that matters for dementia.
A long-term care insurer can lawfully use an ε4 result in underwriting in most states, absent a specific state law, and long-term care is the coverage dementia families most often need. The practical order is: buy or confirm long-term care and life coverage first, then test if there is a clinical reason to. Where testing is clinically warranted — before starting an anti-amyloid drug, for example — do it, but do it knowing the result becomes part of a record you may be asked about.
The diagnostic route that is actually FDA-cleared
The cleared path runs through blood-based biomarkers, not genes. C2N's Precivity AD2 received FDA clearance on August 20, 2026 for people aged 40 and over with signs of cognitive impairment, as Labcorp's neurology treatment-area page describes. It measures evidence of amyloid pathology — which is the thing CMS coverage turns on, and which APOE status cannot establish.
Keep the scale in view too. WHO's dementia fact sheet, updated July 2026, reports more than 57 million people living with dementia worldwide, over 60% of them in low- and middle-income countries, with nearly 10 million new cases a year. And genetics is not the dominant lever. WHO guidelines issued on July 15, 2026 state that up to 45% of dementia risk could be prevented or delayed through modifiable factors — which puts an unchangeable ε4 result alongside blood pressure, hearing, and activity rather than above them.
Frequently Asked Questions
My relative was prescribed Leqembi without an APOE test. Is that a problem?
Not automatically. The FDA label recommends genotyping before treatment to assess ARIA risk but states patients may still be treated if untested. Ask the prescriber how they are monitoring for ARIA instead.
Does a positive ε4 result mean my parent will get Alzheimer's?
No. NIA describes ε4 as raising risk and lowering age of onset, not as determining the outcome, and FDA's review records that up to 75% of people with one copy never develop the disease.
What should I ask a lab before ordering a dementia genetic test?
Ask for its CLIA certificate, the name of the performing lab, the test's validation data, and a written statement of what the result can and cannot be used for.
Can I be turned down for long-term care insurance over an APOE result?
In most states, yes. GINA's protections stop at health insurance and employment and do not extend to long-term care, life, or disability policies.
